Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298523 | 0.81 | GAA (0.51) | GAAALDH1A1SMN1; SMN2ATMNAMPT | |
| SCHEMBL1639886 | 0.81 | GAA (0.51) | GAAALDH1A1SMN1; SMN2ATMNAMPT | |
| SCHEMBL22987577 | 0.80 | GAA (0.59) | GAAALDH1A1SMN1; SMN2ATMNAMPT | |
| SCHEMBL2269043 | 0.79 | KMT2A (0.42) | GAASMN1; SMN2MAPTRAB9APOLB | |
| SCHEMBL27497366 | 0.79 | ADORA2A (0.38) | GAAALDH1A1SMN1; SMN2ATMMAPT | |
| Hydrochloric Acid SCHEMBL10666393 | 0.79 | GAA (0.50) | GAAALDH1A1SMN1; SMN2ATMNAMPT | |
| SCHEMBL1224892 | 0.79 | GAA (0.50) | GAAALDH1A1SMN1; SMN2ATMNAMPT | |
| SCHEMBL27708829 | 0.79 | GAA (0.50) | GAAALDH1A1SMN1; SMN2ATMNAMPT | |
| SCHEMBL22976065 | 0.79 | ALDH1A1 (0.51) | GAAALDH1A1SMN1; SMN2NAMPTMAPT | |
| SCHEMBL28263781 | 0.79 | GAA (0.58) | GAAALDH1A1SMN1; SMN2ATMNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524417-B | One group of 3-methyl-4-formyl pyrazole compound | QINGDAO AGRICULTURAL UNIVERSITY (CN) | 2016-04-27 | — | — | CN | claimed |
| CN-103524417-A | 3-methyl-4-formyl pyrazol compounds | UNIV QINGDAO AGRICULTURAL | 2014-01-22 | — | — | CN | claimed |
| CN-101268055-B | Process for preparing 5-fluoro-1, 3-dialkyl-1H-pyrazole-4-carbonyl fluorides | BAYER CROPSCIENCE AG | 2011-02-16 | — | — | CN | claimed |
| CN-101268055-A | Process for preparing 5-fluoro-1, 3-dialkyl-1H-pyrazole-4-carbonyl fluorides | BAYER CROPSCIENCE AG (DE) | 2008-09-17 | — | — | CN | claimed |
| JP-63196568-A | — | — | None | — | — | JP | disclosed |
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| CN-110105346-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-108570018-B | Amide compound and preparation method and application thereof | 上海晓明检测技术服务有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| CN-108409684-B | N- (2-cyclohexyloxyphenyl) amide compound and preparation method and application thereof | 上海晓明检测技术服务有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-1721899-A1 | Process for the preparation of a carboxamide derivative | Bayer CropScience S.A. (FR) | 2006-11-15 | — | — | EP | disclosed |
| CN-1255384-C | N-pyrazolylcarboxanilides as fungicides | BAYER AGRICULTURE CORP SCIENCE (DE) | 2006-05-10 | — | — | CN | disclosed |
| CN-1745067-A | Biphenylcarboxamide compound | BAYER CROPSCIENCE AG (DE) | 2006-03-08 | — | — | CN | disclosed |
| CN-1222514-C | Pyrazolyl biphenyl carboxamides and the use thereof for controlling undesired microorganisms | BAYER AG (DE) | 2005-10-12 | — | — | CN | disclosed |
| CN-1533380-A | N-pyrazolylcarboxanilides as fungicides | �ݶ�ũ�����ѧ�ɷݹ�˾ | 2004-09-29 | — | — | CN | disclosed |
| CN-1466578-A | Pyrazolyl biphenyl carboxamides and the use thereof for controlling undesired microorganisms | �ݶ�ũ�����ѧ�ɷݹ�˾ | 2004-01-07 | — | — | CN | disclosed |
| US-4792565-A | Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds | MITSUI TOATSU CHEMICALS, INC. (JP) | 1988-12-20 | — | — | US | disclosed |
| JP-S63196568-A | NOVEL PYRAZOLE DERIVATIVE, ITS PRODUCTION AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE | MITSUI TOATSU CHEM INC | 1988-08-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | MCL1, BCL9, BCL2L1 | GAA 2916/4885ALDH1A1 849/4885SMN1; SMN2 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.